Logo

The Line in the Sand Over Personalized Medicine Is Drawn

Aug 16, 2007

Warfarin will soon have a label saying that people with certain genetic variations should start off with a lower initial dose of the blood thinner, reports the Wall Street Journal. Adding this label is part of the Food and Drug Administration's push to promote using genetics to predict patient's reactions to medicine, a major tenet of personalized medicine. This stance, though, is pitting the FDA against major insurers in the US that do not cover the tests.

Breaking News
The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.